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Abstract 
To determine the role of the thiol ester in the folding of human cc?-macroglobulin (a,M) in the active conformation, we have characterized a
recombmant variant of aZM. C949S, expressed in baby hamster kidney cells, that lacks the thiol ester-forming cysteine. C949S a,M behaves like 
methylamine-treated plasma orzM, with correctly formed inter-subunit disulfide bridges. non-covalent association of covalent dimers to form 
tetramers, and exposure of the receptor binding domain, but an inability to inhibit proteinases, and inaccessibility of the bait regions to proteolysis 
We concluded that correct folding of monomers or their association to give tetrameric azM does not require a pre-formed thiol ester. Active azM 
may form in vivo by a two-step process involving initial folding to give a structure resembling that of C949S azM followed by thiol ester formatlon 
and a conformational change that gives the native active state. 
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1. Introduction 
An unusual inkage, a thiol ester, is present in human 
a,-macroglobulin. in cl-macroglobulins from some other 
species, and in the complement proteins C3 and C4 [l]. 
All of these proteins are structurally related, though the 
complement proteins are 190 kDa monomers, whereas 
the a-macroglobulins are mostly dimers or tetramers. In 
human a,-macroglobulin the thiol ester is formed be- 
tween the side chains of cysteine-949 and glutamine three 
residues away at position 952. Limited sequence data on 
some of the other proteins show that the same relation- 
ship of only two intervening residues is maintained and 
that there are highly conserved residues between and 
immediately surrounding the cysteine and glutamine in- 
volved in the thiol ester linkage [2]. 
The thiol ester appears to serve two distinct functions. 
One is to provide a means of covalent binding to target 
proteins, either proteinases in the case of the a-mac- 
*Corresponding author. Fax: (1) (312) 413 0364. 
Abbreviations. a,M, a,-macroglobulin; BHK, baby hamster kidney: 
HNE, human neutrophil elastase; SDS, sodium dodecyl sulfate; PAGE, 
polyacrylanude gel electrophoresis; DMEM, Dulbecco’s modified 
Eagle’s medmm. 
roglobulins, or cell surface proteins and immune com- 
plexes in the case of C3 and C4. The other is to mediate 
a large scale conformational rearrangement, which in the 
case of the dimeric or tetrameric a-macroglobulins is 
sufficient, even in the absence of covalent binding, to 
inhibit proteinases by engulfing them. On non-denatur- 
ing PAGE this is clearly seen as a change in electro- 
phoretic mobility from a slow, active state to a fast, 
inactive state. An important consequence of the confor- 
mational change is to expose receptor binding sites, 
which mediate clearance in the case of cl,-macroglobulin- 
proteinase complexes. 
There are two major questions with respect o the thiol 
ester in both human a,-macroglobulin and in the other 
thiol ester-containing proteins. One is what role the thiol 
ester plays in the correct folding of the protein, and the 
other is what role it plays in maintaining the native con- 
formation of the protein. 
To investigate these questions for human cT?-mac- 
roglobulin and determine whether the thiol ester is 
needed for each of these roles, we have expressed a var- 
iant human a,-macroglobulin, C949S, in which the cyste- 
ine that normally forms the thiol ester has been replaced 
by serine, thereby preventing the formation of a thiol 
ester linkage. We found that the absence of a thiol ester 
did not prevent the a,-macroglobulin polypeptide from 
folding correctly, but that it did prevent adoption of the 
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native conformation of the active inhibitor. Instead, the 
conformation was found to be indistinguishable (as 
judged by electrophoretic mobility) from that which oc- 
curs upon thiol ester cleavage of active wild-type a,- 
macroglobulin by reaction with methylamine, the so- 
called ‘fast-form’. These results suggest that the native 
conformation of human a,-macroglobulin may be gener- 
ated in vivo following complete folding of the protein 
into the fast-form conformation by closure of the thiol 
ester linkage. Closure of the thiol ester linkage, whether 
enzymatically mediated or spontaneously formed, could 
then change the conformation in a manner similar to the 
effect of cyanylation [3,4], to give a reversal of the more 
familiar slow-to-fast conformational change. 
2. Materials and methods 
.? 1. Site-directed Mutagenesis of aZM cDNA 
The a,M expression vector ~1167 [5] was digested with the restriction 
endonucleases BszWI and XbaI to release a 2836-bp fragment contain- 
mg the region covering the residues involved in thiol ester formation. 
This fragment was cloned into M13mp19 that had been modified to 
contain a new 24-bp polylinker (XhoI-BszWI-AflI) between the SphI 
and PsrI sites of the original polyhnker region. An XhoI digest of the 
M13-azM fragment construct released a 965-bp a,M cDNA fragment, 
which was subsequently subcloned into the XhoI site of an M13mp18 
also modified to contain the new XhoI-BsiWI-AflI polylinker. Site- 
directed mutagenesis was performed on the single stranded M13mp18 
construct containing the a,M coding strand using the 21 base oligonu- 
cleotide S-CTG CTC TCC AGA GCC ATA GGG-3’, for which the 
underlined codon represents the cysteine + serine change at residue 
949. Mutagenesis was carried out using the Amersham in vitro Mut- 
agenesis System Verston 2.1, which is based on phosphorothioate- 
modified DNA [&9]. Greater than 80% positive plaques containing the 
desired G + C change at base 4310 (~1167 numbering system) were 
obtained, which was confirmed by sequencing of the single-stranded 
phage DNA. The 965bp fragment containing the changed base at 
position 4310 was cloned back into M13mp19 at the XhoI site to 
regenerate the 2836-bp insert. Phage containing the insert in the correct 
orientation were determined by sequencing the single-stranded form. 
The 2836-bp insert was excised by digestion with BszWI and XbaI and 
ligated into ~1167 that had been cut with the same restriction endonu- 
cleases and purified from the wild-type insert by electrophoresis on 
/3-agarose. Sequencing was carried out on the plasmid to confirm the 
presence of the altered base as position 4310. This gave a new expres- 
sion vector, pl167-C949S, coding for C949S variant azM. 
2.2 Stable transfection of BHK cells 
The procedure used for establishing stably transfected BHK cells 
expressing either wild-type or C949S variant cc,M was the same as we 
have used for stable expression of antithrombin [lo], and a modification 
of the procedure described previously by Boel et al. [5]. BHK 21 cells 
were co-transfected with 20 pg ~1167 (containing either wild-type or 
C949S variant coding sequences), 5pg pRMH140, and 5 pug pSV2dhfr 
by calcium phosphate precipitation in T25 flasks for 5 h. After a 3-min 
glycerol shock, the cells were washed three times with phosphate-buff- 
ered saline and placed in DMEM plus serum. Transient expression of 
a,M was detectable by radial immunodiffusion assay of the 48hr 
growth medium. The cells were split 1:5 into DMEM supplemented 
with 10% fetal bovine serum as well as 400 pg ml-’ G418 and 0.4 PM 
methotrexate. Selection for stably transfected cells expressing the high- 
est levels of azM was carried out over 4 weeks by gradually increasing 
the concentration of methotrexate to 10 fiM while keening the G418 
concentration constant. The level of expression of the polyclonal cul- 
ture after this period was 32&106 cells/24 h for the C949S variant a,M. 
For punficatibn of large amounts of azM. cells were grown to co&u- 
ence in roller bottles and cycled every 24 h between medium devoid of 
277 
fetal bovine serum and drugs and medium supplemented with these 
items. Only medium from the serum-free cycles was harvested. 
2.3. Isolatron of a,M 
Plasma cc,M was isolated from outdated human plasma obtained from 
the Vanderbilt Blood Bank by chromatography on zinc chelate resin, 
Cibachron blue gel, and AcA22, as described previously [I 11. Recombi- 
nant human azM, both wild-type and C949S variant proteins, were 
Isolated from pooled serum-free growth medium by the protocol of 
Dangott and Cunningham [ll], but with omission of the Cibachron 
blue and AcA22 chromatography steps, which were judged to be unnec- 
essary for isolation of pure azM. The a,M was judged to be homogene- 
ous by SDS-PAGE. Concentrations of all forms of azM were deter- 
mined spectrophotometrically using the extinction coefficient for the 
plasma protein of 564,000 M-’ . cm-’ [12]. 
2 4. Polyacrylamide gel electrophoresis 
Nondenaturing PAGE was carried out on 5% acrylamide slab gels 
[13]. SDS-PAGE was carried out on 7.5% slab gels according to the 
procedure of Laemmli [14]. Unless otherwise indicated, all samples for 
SDS-PAGE were denatured and reduced for 45 min at 37°C in buffer 
containing 1% SDS and 0.8% dithiothreitol. 1 mM phenylmethylsulfon- 
ylfluoride was added to aZM samples containing proteinase to prevent 
additional cleavage of the azM during denaturation. Where molecular 
weight standards were included, they consisted of myosin 200 kDa; 
B-galactosidase, 116.3 kDa; phosphorylase B. 97.4 kDa; serum albu- 
min, 66.2 kDa; ovalbumin, 45 kDa; carbonic anhydrase. 31 kDa, tryp- 
sin inhibitor. 21.5 kDa: lysozyme, 14.4 kDa; and aprotinin. 6.5 
kDa. 
2.5. Assays 
Trypsin trapping assays were carried out as described previously [15] 
by measurmg residual trypsin enzymatic activity following additton of 
an excess of soybean trypsin inhibitor to complex any non-a,M-trapped 
trypsin. Trypsin activity was measured spectrophotometrically using 
the chromogenic substrate N-tosyl-L-arginine methyl ester. 
2.6. Muter&s 
Reagents, enzymes, and ohgonucleotides were obtained as follows. 
Low melting point agarose, maximum efficiency DHSaF’ IQ competent 
E. co/i, DMEM, and G418 from GibcolBRL. Sequenase version 2.0 
DNA sequencing kit from United States Btochemical Corporation. 
M13mp18 (RF), M13mp19 (RF), and BszWI from Boehringer 
Mannheim. XbaI, PstI, SphI. XhoI, /I-agarase 1, T4 DNA ligase. and 
T4 polynucleotide kinase from New England Biolabs. Plasmid purifica- 
tion kits from Qiagen. Oligonucleotide-directed in vitro mutagenesis 
system kit version 2.1 from Amersham. [a-“P]dATP and [Y-~‘P]ATP 
from New England Nuclear. Radial Immunodiffusion plates for human 
a2M from The Binding Site, Inc. Methotrexate ((+)-amethopterin), 
phenylmethsulfonylfluoride, and N-tosyl-L-arginine methyl ester from 
Sigma. Trysin from Cooper Biomedical. Human neutrophil elastase 
from Athens Research and Technology, Inc. Fetal bovine serum, pre- 
mium grade from Bioproducts for Science, Inc. 
3. Results 
3.1. Structural properties of C949S variant a2M 
To determine whether the mutation of cysteine-949 to 
serine had affected the ability of the polypeptide to fold 
in the correct manner, to form the correct inter-subunit 
disulfide bonds, and to oligomerize to form a tetramer, 
the structural properties of the recombinant C949S vari- 
ant of a,M were determined by several methods. The 
immunoreactivity of the protein towards anti-human 
a,M polyclonal antibody was examined in a radial im- 
munodiffusion plate assay. The C949S cl,M was im- 
munoreactive and gave a degree of interaction consistent 
with the total amount of azM present (estimated inde- 
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pendently from intensity on SDS-PAGE). This indicated 
that the protein had folded sufficiently well to be secreted 
into the medium and possessed some or all of the epi- 
topes present in wild-type or plasma azM. 
On a polyacrylamide gel run under non-denaturing 
conditions the C949S variant a2M had the same mobility 
(Fig. 1, lane 7) as wild-type or plasma a,M that had been 
treated with trypsin or HNE (Fig. 1, lanes 2,3,5 and 6), 
but different mobility from native wild-type or plasma 
forms (Fig. I, lanes 1 and 4)‘ Reaction of C949S with 
either trypsin or HNE did not change its mobility (Fig. 
1, lanes 8 and 9) consistent with it already being in the 
fast-form conformation. Since the mobility under non- 
denaturing conditions depends on the tertiary as well as 
the primary structure of a protein, this indicated that the 
overall structure resembled that of fast form azM both 
in the folding of the monomer and the association to 
form tetrameric ff,M. 
Upon treatment of C949S variant with 1% SDS, the 
protein changed mobility on a non-denaturing el from 
that of tetrameric a,M (Fig. 2, lanes I-5) to the same 
position as the 360-kDa disul~de-linked half molecules 
of plasma and wild-type a,M on a polyacrylamide gel 
(Fig. 2, lanes 6-10). Following reduction, the variant 
gave a single band at he same position as the lgO-kDa 
monomer position (Fig. 3, lanes 1,4, and 7). These results 
indicated that the correct disulfides had been formed 
between monomers to give covalently linked dimers and 
that no thiol ester was present in the molecule. Heating 
the C949S sample at 90°C for 5 min prior to running on 
SDS-PAGE did not result in the heat fragmentation that 
is thought to result from intramolecular attack of the 
amide nitrogen of Gin 952 on the carbonyl of the thiof 
ester (Fig. 4A, lane IO), consistent with the absence of a 
thiol ester. 
3.2. Functional properties of C949S variant a,M 
To determine whether the fast electrophoretic mobility 
of the C949S variant cr,M on non-denaturing PAGE 
indicated that the variant had also lost the ability to 
interact with and inhibit proteinases. we examined the 
interaction of the protein with trypsin and human neu- 
trophil elastase (HNE) and compared the behavior with 
that of wild-type recombinant and plasma azM. With 
both trypsin and HNE the bait region of plasma a,M 
123456789 
Fig. 1. Demonstration of fast-form mobility for C949S a,M on non- 
denaturing polyacrylamide gel. Lanes 1-3, human plasma azM; lanes 
4-6, wild-type recombinant a2M; lanes 779. C949S variant recombinant 
aZM. For each protein the first lane is unreacted, the second after 
reaction wtth trypsin, and the third after reaction with HNE. 
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Fig. 2. SDS-induced diss~iation of a,M species into disulfide-ijnk~ 
half molecutes on a 5% poIyacrylam]de gel run under non-denaturing 
non-reduced conditions. Lane 1. native plasma a,M: lane 2, methylam- 
ine-treated plasma a2M; lane 3. wild-type recombinant azM; lane 4, 
methylamine-treated recombinant aZM; lane 5. C949S variant recombi- 
nant a,M. Lanes 6-10, are the same samples as in lanes I-5, respec- 
tively. but after incubation in 1% SDS prior to loading. 
was completely cleaved to give the characteristic bands 
on SDS-PAGE at about 90 kDa, corresponding to 
cleaved monomer as well as fainter high molecular 
weight bands near the top of the gel corresponding to 
monomer fragments cova~ently cross-linked to the pro- 
teinase via ~-lysyl-~-glutamyl bonds (Fig. 3, lanes 1-3) 
(the cross linked bands are either absent or of greatly 
reduced intensity in the HNE sample, probably as a 
result of the absence of lysine residues in HNE). Almost 
identical behavior was found with recombinant wild- 
type a,M (Fig. 3, lanes 46). The C949S variant, how- 
ever, was only slightly susceptible to bait region cleavage 
by either trypsin or elastase (Fig. 3, lanes 7-9). 
To determine if the limited proteolysis of the bait re- 
gion of the C949S variant simply reflected a much slower 
rate of reaction with trypsin compared with plasma or 
wild-type a,M, the variant was incubated with 2.2 eq. 
trypsin for different periods of time before inactivation 
of the proteinase. For comparison, methylamine-treated 
plasma a,M was similarly incubated with trypsin. SDS- 
PAGE of the C949S reaction mixtures showed that a 
small fraction of the bait regions is accessible to trypsin 
12 3 4 5 6 78 910 
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Fig. 3. Ability of proteinases to react with plasma, wild-type recombi- 
nant, and C949S recombinant azMs from appearance of cleavage and 
cross-linkage products on reduced SDS-PAGE. Lanes l-3. plasma 
azM; lanes 4-6, recombinant wild-type a,M; lanes 7-9. C949S recombi- 
nant variant aZM. lane IO. high molecular weight markers, as described 
in section 2.4, from myosin to carbonic anhydrase. For each protem the 
first lane contains unreacted azM, the second azM reacted with 2.2 eq. 
trypsin, and the third lane aZM reacted with 2.2 eq. FINE. 
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Fig. 4. Inaccessibility of the bait region to proteolysis by ttypsin in 
me~ylamine-treaty plasma a,M and C949S r~ombinant variant a,M 
demonstrated by SDS-PAGE of incubations of the a,Ms with trypsin 
for different imes. (A) C949S variant recombinant a,M. (B) Methylam- 
me-treated plasma a,M. Lanes 1 through 7 represent incubations with 
trypsin for 0,5,10,15,30,60, and 120min. Lane 8 contains broad range 
molecular weight standards as described in section 2.4. Lane 9 in each 
panel contains heat-treated native a,M and shows the characteristic 
heat fra~entation bands at about 120 and 60 kDa. Lane 10 in panel 
4. contains heat-treated C949S a,M, and lane 10 in panel B contains 
heat treated methylamine-treated plasma a,M. Lane IOA shows no heat 
fragmentation band and lane lob shows only a trace, presumably re- 
sulting from the presence of low levels of intact thiol ester prior to 
heating. 
and is cleaved rapidly within the first few minutes (Fig. 
4A, lanes 1 and 2). Most of the bait regions are not 
accessible to trypsin and remain uncleaved even after 
incubation with trypsin for 2 h (Fig. 4A, lanes 2-7). The 
ability of trypsin to cleave a small fraction of the bait 
regions was not, however, restricted to the C9498 vari- 
ant, since methylamine-treated plasma a,M, which is 
also in the fast-form conformation, showed a similar 
pattern of limited cleavage (Fig. 4B, lanes l-7). 
A trypsin trapping assay was performed on the C949S 
variant a,M to determine if the limited bait region 
cleaved seen above corresponded to a small amount of 
trypsin binding. One sample of the variant was incubated 
with 2.2 eq. trypsin for 5 min and another for 1 h. No 
trypsin activity was found associated with the a,M. In 
contrast, plasma al?M under the same conditions gave a 
value of 1.6 mol trypsin trapped/m01 a,M. 
The final comparison between C949S a,M and meth- 
ylamine-treated plasma a,M was in the behavior to- 
wards papain. Following reaction of plasma a,M with 
either proteinase or methylamine, the receptor recogni- 
tion domain is exposed and can be cleaved s~i~cally 
by reaction with papain [16]. Native a,M does not show 
this specific cleavage. A comparison of the papain-diges- 
tion patterns of native plasma a,M, methylamine-treated 
plasma a,M, and C949S a,M, showed that the latter 
behaved like methyl~ine-treated a,M, being able to 
release a fragment that ran on SDS-PAGE at the same 
positions as purified receptor binding domain (Fig. 5), 
whereas no such fragment release was observed with the 
native protein (Fig. 5, lane 2). Two bands are normally 
observed for the receptor recognition domain corre- 
sponding to non-~ycosylated and glycosylated forms 
(Fig. 5, lane 7) [l&17]. In plasma cr,M the glycosylated 
form dominates (Fig. 5, lanes 4 and 7), whereas in the 
recombinant protein the non-glycosylated form domi- 
nates (Fig. 5, lane 6). 
4. Discussion 
We have shown by a number of criteria that the C949S 
variant of a,M, despite being unable to form a thiol 
ester, could fold into a form that was indistin~ishable 
from that of methylamine-treated plasma azM. Thus 
C949S a,M showed ‘fast-form’ electrophoretic mobility 
under non-denaturing conditions and possessed no pro- 
teinase inhibitory capacity. The latter was judged not to 
be due to incorrect folding, however, since the bait re- 
gions showed the same resistance to tryptic cleavage as 
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Fig. 5. Release of receptor ecognition domain from C949S and meth- 
ylamine-treated plasma ozMs, but not from native a?M upon reaction 
with papain. Silver stained 12% SDS polyacrylamide gel run under 
non-reducing conditions. Lanes 1 and 2. nativeplasmaazM; lanes 3 and 
4, methylamine-treated plasma a,M; lanes 5 and 6, C949S a,M; lane 
7, purified receptor recognition domain. Lane 8 contains molecular 
weight markers as described in section 2.4. Lanes I,3 and 5 are samples 
unreacted with papain; lanes 2.4 and 6 are cc?M samples incubated with 
papain for 5 h. The conditions of the incubation were 0.4 mg/ml a,M, 
and a ratio of a,M to papain of 481 (w/w). Note that the receptor 
recognition domain occurs as two bands. Both have the same polypep- 
tide structure but differ in glycosylation. The higher M.W. band carries 
one carbohydrate chain, whereas the lower band carries none. It ap- 
pears that the relative proportions of glycosylated and non-glycosylated 
domain differ between the plasma protein and the recombinant BHK- 
derived protein, with more glycosylated form for the former and more 
non-glycosylated form for the latter. 
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methylamine-treated CQM. Denatured or incorrectly 
folded a&l would be expected to have a number of 
potential tryptic cleavage sites accessible to proteinase. 
The protein also appeared to have the same tetrameric 
form as both native and methylamine-treated plasma 
a,Ms, being composed of a non-covalently associated 
pair of disulfide-linked dimers. In addition, the variant 
could also release the receptor recognition domain upon 
cleavage with papain. This cleavage is specific for the 
fast-form methylamine-treated structure of d2M. 
These results show that the thiol ester is not required 
for folding of the individual domains of cl,M, for correct 
disulfide-bond formation both within and between mon- 
omers, and for the correct association of the disulfide- 
linked half molecules to give the tetramer. However, the 
behavior of the variant as a non-inhibitory fast-form of 
a,M, rather than an active slow-form species, again dem- 
onstrates the close relationship between the presence of 
an intact thiol ester and the maintenance of the active 
conformation. This relationship is a subtle one, which 
may not involve a large energy difference between the 
two states. Thus cyanylation or iodination of the free SH 
group in fast-form plasma a,M can reverse the slow-to- 
fast confo~ational change even though the thiol ester 
is not re-formed [4]. In bovine azM, cleavage of the thiol 
ester alone by methylamine-treatment is not sufficient o 
cause the slow-to-fast conformational change [l I]. In- 
stead both thiol ester cleavage and bait region cleavage 
must occur for the conformational change to occur. In 
chicken ovostatin there is no thiol ester, but a proteinase- 
induced slow-to-fast conformational change still occurs 
1183. Also, it has been shown for C3 that the thiol ester 
can spontaneously reform after cleavage by either am- 
monia or methylamine, with a dt? for the process of 
+5.2 kcal. mol-‘, corresponding to a Kd for the forma- 
tion of slow form C3 and ammonia of about 150 ,uM [ 191. 
With appropriately low concentrations of NH, at physi- 
ological pH, this could readily result in formation of the 
thiol ester and a conformational change to the slow- 
form, active species in C3 and also, presumably, in 
a,M. 
These results suggest a folding pathway for active alM 
that does not require the thiol ester to give the correct 
domain folding or monomer-monomer interactions, but 
only to provide the small energy change necessary to 
move the equilibrium in favor of the active conforma- 
tion. This shift in equilibrium can be provided by other 
means, such as cyanylation of the cysteine, cross-linking 
with cis-platinum [20,21], or other undefined interactions 
such as must occur in bovine or,M or ovostatin. 
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